These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22736376)

  • 41. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
    Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
    J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
    Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical characterisation of 111In-DTPA-trastuzumab.
    Lub-de Hooge MN; Kosterink JG; Perik PJ; Nijnuis H; Tran L; Bart J; Suurmeijer AJ; de Jong S; Jager PL; de Vries EG
    Br J Pharmacol; 2004 Sep; 143(1):99-106. PubMed ID: 15289297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment.
    Liu P; Boyle AJ; Lu Y; Reilly RM; Winnik MA
    Biomacromolecules; 2012 Sep; 13(9):2831-42. PubMed ID: 22871127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
    Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
    J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
    Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA
    J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
    Hu M; Scollard D; Chan C; Chen P; Vallis K; Reilly RM
    Nucl Med Biol; 2007 Nov; 34(8):887-96. PubMed ID: 17998090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
    Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
    Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-produced Thorium for Radioimmunotherapy of EGFR-overexpressing Carcinomas.
    Bravo MG; Egorova BV; Vasiliev AN; Lapshina EV; Ermolaev SV; Durymanov MO
    Curr Radiopharm; 2023 Jun; 16(3):233-242. PubMed ID: 36809934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
    Hoang B; Ekdawi SN; Reilly RM; Allen C
    Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.
    Barta P; Laznickova A; Laznicek M; Vera DR; Beran M
    J Labelled Comp Radiopharm; 2013 May; 56(5):280-8. PubMed ID: 24285372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [
    Chan C; Prozzo V; Aghevlian S; Reilly RM
    EJNMMI Radiopharm Chem; 2022 Dec; 7(1):33. PubMed ID: 36542157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.
    Cornelissen B; Waller A; Able S; Vallis KA
    Mol Cancer Ther; 2013 Nov; 12(11):2472-82. PubMed ID: 23963362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
    du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
    Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C
    Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Favorable tumor uptake and nuclear transport of Auger electrons by nuclear targeting with 111In-trastuzumab in an intraperitoneal tumor mouse model.
    Keiko Li H; Hasegawa S
    Nucl Med Commun; 2022 Jul; 43(7):763-769. PubMed ID: 35506286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
    Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.